The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: Hi. Thank you both very much. It's been a great presentation. So I actually have questions for both Dr. Markham and Dr. McAlpine. Let's start with
Dr. McAlpine. So specifically in your current studies, you noted an elevation of phospho-tau. Can you talk a little bit about what isoform you identified
being elevated?
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: Got it. So total tau, not a specific isoform of total correlated tau. Okay, got it. Now I want to quickly ask you also, Dr. McAlpine, because your
experience in this field is interesting, and it is a very new field. I've seen a lot of literature suggesting different proposed subtypes of long COVID:
those with the neurological conditions, those more in the fibromyalgia kind of conditions, neuropathy-like styles. So how does that type of, I guess,
kind of compartmentalization or kind of potential subgrouping impact this trial? And how do you actually think about that in terms of this pathology?
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: I think a little bit, yes. There's obviously a lot of questions about the entire space.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
APRIL 10, 2025 / 2:00PM, BIVI.OQ - BioVie Inc to Host Key Opinion Leader (KOL) Event
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: Fantastic. Dr. Markham and kind of the rest of the BioVie team, I mean, kind of going off of that for a little bit, obviously, you're looking at very
strong exclusion criteria, utilizing both subjective and objective cognitive measures along with fatigue. But there's a very likely chance that this
patient group that you look at might be divergent or might be subdued within it. Do you have any planned kind of pre-specified subgroup analysis
you're going to plan to look at post Phase 2, which might be informative for a Phase 3 program?
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: Got it. And do you plan to do those both just in the pre and the post phase for patients, or would you like to also do interim every X number of
weeks to get a more of a longitudinal effect of bezisterim on patient outcomes?
Question: Tyler Bussian - Brookline Capital Markets, LLC - Analyst
: Great. Well, thank you both. Thank everybody so much. This has been a fantastic presentation.
|
